FORTUNE 500

			Revenues		Profits
Rank	Company	Fortune 500 rank	$ millions	% change from 2008	$ millions	% change from 2008
1	Johnson & Johnson	33	61,897.0	-2.9	12,266.0	-5.3
2	Pfizer	40	50,009.0	3.5	8,635.0	6.6
3	Abbott Laboratories	75	30,764.7	4.2	5,745.8	17.7
4	Merck	85	27,428.3	15.0	12,901.3	65.2
5	Eli Lilly	112	21,836.0	7.2	4,328.8	N.A.
6	Bristol-Myers Squibb	114	21,634.0	1.3	10,612.0	102.2
7	Amgen	159	14,642.0	-2.4	4,605.0	9.7
8	Gilead Sciences	324	7,011.4	31.4	2,635.8	31.1
9	Mylan	412	5,092.8	-0.9	232.6	N.A.
10	Genzyme	458	4,515.5	-1.9	422.3	0.3
11	Allergan	459	4,503.6	2.3	621.3	7.4
12	Biogen Idec	471	4,377.3	6.8	970.1	23.9

Rank	Company	Revenues %	Assets %	Stockholders' Equity %
1	Johnson & Johnson	19.8	13.0	24.2
2	Pfizer	17.3	4.1	9.6
3	Abbott Laboratories	18.7	11.0	25.1
4	Merck	47.0	11.5	21.8
5	Eli Lilly	19.8	15.8	45.5
6	Bristol-Myers Squibb	49.1	34.2	71.5
7	Amgen	31.5	11.6	20.3
8	Gilead Sciences	37.6	27.2	41.4
9	Mylan	4.6	2.2	7.4
10	Genzyme	9.4	4.2	5.5
11	Allergan	13.8	8.2	12.9
12	Biogen Idec	22.2	11.3	15.6

		Earnings Per Share	Total Return to Investors		Employees
Rank	Company	1999-2009 Annual growth (%)	1999-2009 Annual rate (%)	2009 (%)	Number	% change from 2008
1	Johnson & Johnson	11.6	5.5	11.4	115,500	-2.7
2	Pfizer	4.1	-2.6	8.6	116,500	42.4
3	Abbott Laboratories	8.9	7.2	4.5	72,868	5.9
4	Merck	8.7	-2.2	26.6	100,000	81.2
5	Eli Lilly	4.8	-3.4	-5.9	40,360	-0.3
6	Bristol-Myers Squibb	10.0	-4.6	15.1	28,000	-20.0
7	Amgen	16.0	-0.6	-2.0	17,100	1.8
8	Gilead Sciences	N.A.	29.0	-15.4	3,874	12.6
9	Mylan	-2.9	5.7	86.3	14,000	3.7
10	Genzyme	4.4	8.1	-26.2	12,000	9.1
11	Allergan	11.3	10.6	56.9	8,300	-5.0
12	Biogen Idec	27.9	5.0	12.3	4,750	1.0